-
脓毒症是指因感染引起的宿主反应失调导致的危及生命的器官功能障碍[1],其中急性肾损伤(acute kidney injury, AKI)是严重脓毒症较常见并发症,有研究[2]指出需要透析的脓毒症相关AKI病人死亡率高达60%~80%。最新国内外脓毒症指南均推荐使用降钙素原(procalcitonin, PCT)来评估脓毒症病人的临床疗效以及指导抗菌药物治疗[3-4]。此外有专家共识[5]也指出:在重症医学科(intensive care unit, ICU)中,PCT也应用于接受肾脏替代治疗的病人,但需谨慎解释PCT结果,然而共识并没有给出更详细的建议。目前连续肾替代治疗(continuous renal replacement therapy, CRRT)是脓毒症相关AKI病人常用的治疗手段[6],我们知道病人的肾功能状态[7]、CRRT[8]以及感染状态[9]均会影响血清PCT结果。CRRT对血清PCT水平产生的影响,可能会导致医生对病情的误断、掩盖病人的真实情况。本研究通过对CRRT期间PCT水平趋势的研究,发现其在该类病人预后判断方面的价值,现作报道。
-
2组病人在性别、年龄、APACHEⅡ、SOFA评分及KDIGO分期方面差异均无统计学意义(P>0.05),具有可比性,第28天病死率为60%(见表 1)。
分组 n 男 年龄/岁 SOFA评分/分 APACHEⅡ评分/分 KDIGO分期 2期 3期 存活组 10 6 60.00±6.77 10.30±1.89 23.50±6.06 2 8 死亡组 15 9 66.93±13.21 12.33±3.27 23.67±6.79 3 12 t — — 1.47 1.77 0.06 — P — >0.05* >0.05 >0.05 >0.05 >0.05* *示Fisher确切概率 表 1 研究对象的基础资料(x±s)
-
2组病人在不同时间点血清PCT、WBC、CRP水平比较差异均无统计学意义(P>0.05),但2组间血清PCT清除率在下机24 h比较差异均有统计学意义(P < 0.01)(见表 2)。
分组 n 上机前 上机12 h 上机24 h 下机24 h PCT/(ng/mL) 存活组 10 31.97±23.57 19.17±13.87 11.38±8.71 7.52±5.95 死亡组 15 22.06±21.45 14.87±13.60 12.01±10.84 15.00±11.24 t — 1.09 0.77 0.15 1.92 P — >0.05 >0.05 >0.05 >0.05 WBC/×(109/L) 存活组 10 16.47±7.36 16.75±5.52 14.53±4.45 14.90±4.26 死亡组 15 18.03±7.90 17.70±7.95 17.74±8.04 18.08±8.11 t — 0.50 0.33 0.76 1.13 P — >0.05 >0.05 >0.05 >0.05 CRP/(mg/L) 存活组 10 124.31±64.01 119.91±61.08 110.96±52.96 89.22±61.39 死亡组 15 129.31±77.78 139.89±65.54 139.08±65.66 111.47±69.13 t — 0.17 0.77 1.13 0.82 P — >0.05 >0.05 >0.05 >0.05 PCT清除率/% 存活组 10 — 37.46±8.28 34.91±18.42 34.80±13.70 死亡组 15 — 27.65±20.95 14.51±29.91 51.01±45.40 t — — 1.40 1.92 5.77 P — — >0.05 >0.05 < 0.01 表 2 不同时间点血清PCT、WBC、CRP及PCT清除率比较(x±s)
-
上机12 h、上机24 h PCT清除率的ROC曲线下面积分别为0.620、0.693,下机24 h PCT清除率的ROC曲线下面积为0.980(95%CI:0.934~1.000),以21.5%作为cut-off值,敏感度为90.0%,特异度为100.0%(见表 3)。
PCT清除率 AUC cut-off值/% 95%CI P 敏感度/% 特异度/% 约登指数 上机12 h 0.620 40.5 0.390~0.850 >0.05 40.0 93.3 0.33 上机24 h 0.693 18.1 0.479~0.907 >0.05 40.0 40.0 0.60 下机24 h 0.980 21.5 0.934~1.000 < 0.01 90.0 100.0 0.90 表 3 不同时间点PCT清除率对预后的预测价值
脓毒症相关急性肾损伤在连续肾替代治疗早期降钙素原的预测价值
Predictive value of procalcitonin in the early stage of continuous renal replacement therapy of sepsis-associated acute kidney injury
-
摘要:
目的探讨降钙素原(PCT)在连续肾替代治疗(CRRT)早期的水平趋势对脓毒症相关急性肾损伤(AKI)病人预后的预测价值。 方法选择诊断为脓毒症相关AKI并且行CRRT的25例病人,根据第28天预后情况分为存活组(n=10)和死亡组(n=15)。检测CRRT后不同时间点(上机前,上机12 h、24 h及下机24 h)血清PCT、白细胞计数(WBC)、C反应蛋白(CRP)水平,计算不同时间点PCT清除率(%),并记录一般临床资料,比较2组间的差异,利用受试者工作曲线(ROC曲线)评估其对预后的预测价值。 结果2组病人在不同时间点血清PCT、WBC、CRP水平比较差异均无统计学意义(P>0.05),但2组间血清PCT清除率在下机24 h比较差异均有统计学意义(P < 0.01)。上机12 h、上机24 h PCT清除率的ROC曲线下面积分别为0.620、0.693,下机24 h PCT清除率的ROC曲线下面积为0.980(95%CI:0.934~1.000),以21.5%作为cut-off值,敏感度为90.0%,特异度为100.0%。 结论脓毒症相关AKI病人在CRRT早期时,PCT、CRP、WBC水平及CRRT运行期间的PCT清除率对预后预测价值有限,下机24 h PCT清除率对预后具有较高的预测价值。 Abstract:ObjectiveTo evaluate the prognostic value of procalcitonin (PCT) in the early stage of continuous renal replacement therapy (CRRT) of septic-associated acute kidney injury (AKI). MethodsTwenty-five sepsis-associated AKI patients treated with CRRT were divided into the survival group (n=10) and death group (n=15) according to 28 days prognosis.At different time points after CRRT treatment, the serum PCT, white blood cell ount (WBC), C reactive protein (CRP) levels in two groups were detected, and the PCT clearance (%) was calculated.The general clinical data in two groups were recorded, and the difference of which was compared between two groups.The receiver operating curve (ROC) was used to evaluate its prognostic value. ResultsThere was no statistical significance in the levels of serum PCT, WBC and CRP between two groups at different time points (P>0.05), but the difference of serum PCT clearance between two groups was statistically significant after 24 h of CRRT shutdown (P < 0.01).The area under the ROC curve of the clearance rates of 12 h and 24 h PCT after starting CRRT were 0.620 and 0.693, respectively.The area under the ROC curve of the clearance rate of 24 h PCT after CRRT was 0.980 (95% CI:0.934-1.000).Using 21.5% as the cut-off value, the sensitivity was 90.0%, and the specificity was 100.0%. ConclusionsIn the early CRRT stage of sepsis-associated AKI patients, inflammatory indicators (PCT, WBC and CRP) have limited prognostic value.The clearance rate of 24 h PCT after CRRT shutdown has a high prognostic value. -
Key words:
- procalcitonin /
- continuous renal replacement therapy /
- sepsis /
- acute kidney injury /
- predictive value
-
表 1 研究对象的基础资料(x±s)
分组 n 男 年龄/岁 SOFA评分/分 APACHEⅡ评分/分 KDIGO分期 2期 3期 存活组 10 6 60.00±6.77 10.30±1.89 23.50±6.06 2 8 死亡组 15 9 66.93±13.21 12.33±3.27 23.67±6.79 3 12 t — — 1.47 1.77 0.06 — P — >0.05* >0.05 >0.05 >0.05 >0.05* *示Fisher确切概率 表 2 不同时间点血清PCT、WBC、CRP及PCT清除率比较(x±s)
分组 n 上机前 上机12 h 上机24 h 下机24 h PCT/(ng/mL) 存活组 10 31.97±23.57 19.17±13.87 11.38±8.71 7.52±5.95 死亡组 15 22.06±21.45 14.87±13.60 12.01±10.84 15.00±11.24 t — 1.09 0.77 0.15 1.92 P — >0.05 >0.05 >0.05 >0.05 WBC/×(109/L) 存活组 10 16.47±7.36 16.75±5.52 14.53±4.45 14.90±4.26 死亡组 15 18.03±7.90 17.70±7.95 17.74±8.04 18.08±8.11 t — 0.50 0.33 0.76 1.13 P — >0.05 >0.05 >0.05 >0.05 CRP/(mg/L) 存活组 10 124.31±64.01 119.91±61.08 110.96±52.96 89.22±61.39 死亡组 15 129.31±77.78 139.89±65.54 139.08±65.66 111.47±69.13 t — 0.17 0.77 1.13 0.82 P — >0.05 >0.05 >0.05 >0.05 PCT清除率/% 存活组 10 — 37.46±8.28 34.91±18.42 34.80±13.70 死亡组 15 — 27.65±20.95 14.51±29.91 51.01±45.40 t — — 1.40 1.92 5.77 P — — >0.05 >0.05 < 0.01 表 3 不同时间点PCT清除率对预后的预测价值
PCT清除率 AUC cut-off值/% 95%CI P 敏感度/% 特异度/% 约登指数 上机12 h 0.620 40.5 0.390~0.850 >0.05 40.0 93.3 0.33 上机24 h 0.693 18.1 0.479~0.907 >0.05 40.0 40.0 0.60 下机24 h 0.980 21.5 0.934~1.000 < 0.01 90.0 100.0 0.90 -
[1] SINGER M, DEUTSCHMAN CS, SEYMOUR CW, et al.The third international consensus definitions for sepsis and septic shock(Sepsis-3)[J].JAMA, 2016, 315(8):801. [2] DOIK.Role of kidney injury in sepsis[J].J Intensive Care, 2016, 4(1):17. [3] 中国医师协会急诊医师分会, 中国研究型医院学会休克与脓毒症专业委员会.中国脓毒症/脓毒性休克急诊治疗指南(2018)[J].中国急救医学, 2018, 38(9):741. [4] RHODES A, EVANS LE, ALHAZZANI W, et al.Surviving sepsis campaign:international guidelines for management of sepsis and septic shock:2016[J].Intensive Care Med, 2017, 43(3):304. [5] BARTOLETTI M, ANTONELLI M, BRUNO BLASI FA, et al.Procalcitonin-guided antibiotic therapy:an expert consensus[J].Clin Chem Lab Med, 2018, 56(8):1223. [6] PETERS E, ANTONELLI M, WITTEBOLE X, et al.A worldwide multicentre evaluation of the influence of deterioration or improvement of acute kidney injury on clinical outcome in critically ill patients with and without sepsis at ICU admission:results from TheIntensive Care Over Nations audit[J].Crit Care, 2018, 22(1):188. [7] AMOUR J, BIRENBAUM A, LANGERON O, et al.Influence of renal dysfunction on the accuracy of procalcitonin for the diagnosis of postoperative infection after vascular surgery[J].Crit Care Med, 2008, 36(4):1147. [8] HONORÉPM, DE BELS D, SPAPEN HD.An update on membranes and cartridges for extracorporeal blood purification in sepsis and septic shock[J].Curr Opin Crit Care, 2018, 24(6):463. [9] 降钙素原急诊临床应用专家共识组.降钙素原(PCT)急诊临床应用的专家共识[J].中华急诊医学杂志, 2012, 21(9):944. [10] VINCENT JL, MORENO R, TAKALA J, et al.The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure[J].Intensive Care Med, 1996, 22(7):707. [11] KHWAJA A.KDIGO clnical ipractice guidelines for acute kidney injury[J].Nephron Clin Pract, 2012, 120(4):c179. [12] JJV MM, PARFREY PS, AL E.KDIGO Clinical practice guideline for anemia in Chronic Kidney Disease[J].Kidney International Supplements, 2012, 2(4):279. [13] VIJAYAN A L, VANIMAYA, RAVINDRAN S, et al.Procalcitonin:a promising diagnostic marker for sepsis and antibiotic therapy[J].J Intensive Care, 2017, 5(1):51. [14] ENGUIXARMADA A, ESCOBARCONESA R, LA TORRE AG, et al.Usefulness of several biomarkers in the management of septic patients:C-reactive protein, procalcitonin, presepsin and mid-regional pro-adrenomedullin.[J].Clin Chem Lab Med, 2016, 54(1):163. [15] CALDINI A, CHELAZZI C, TERRENI A, et al.Is procalcitonin a reliable marker of sepsis in critically ill septic patients undergoing continuous veno-venous hemodiafiltration with "high cut-off" membranes (HCO-CVVHDF)?[J].Clin Chem Lab Med, 2013, 51(11):e261. [16] MAT NOR MB, MD RALIB A.Procalcitonin clearance for early prediction of survival in critically ill patients with severe sepsis[J].Crit Care Res Pract, 2014, 2014:819. [17] RYU JA, YANG JH, LEE D, et al.Clinical usefulness of procalcitonin and c-reactive protein as outcome predictors in critically ill patients with severe sepsis and septic shock[J].PLoS One, 2015, 10(9):e138. [18] DE AZEVEDO, JOSÉ RA, TORRESO JM, et al.Prognostic evaluation of severe sepsis and septic shock:procalcitonin clearance vs delta Sequential organ failure assessment[J].J Crit Care, 2015, 30(1):219.e9. [19] RUIZ-RODRÍGUEZ JC, CABALLERO J, RUIZ-SANMARTIN A, et al.Usefulness of procalcitonin clearance as a prognostic biomarker in septic shock.A prospective pilot study[J].Med Intensiva, 2012, 36(7):475. [20] KADE G, LITERACKI S, RZESZOTARSKA A, et al.Removal of procalcitonin and selected cytokines during continuous veno-venous hemodialysis using high cutoff hemofilters in patients with sepsis and acute kidney injury[J].Blood Purif, 2018, 46(2):153.